$1.15
0.054.55%
Last update: Nov 11, 6:15 PM
INmune Bio Inc
INMBNASDAQ
INmune Bio fell 27.6% from $1.52 to $1.10, behind the S&P 500's +11.2%. Its worst day was Nov 5 (−11.7%), and its low came Nov 10 at $1.10.
Nov 12, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.18 beat the $-0.27 estimate on $0.00 revenue.
−0.9% · S&P 500 +2.9%
EPS of $-0.20 beat the $-0.21 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
0.0% · S&P 500 +0.8%
INmune Bio shares rose 11.5%, while the S&P 500 rose 1.0%.
+11.5% · S&P 500 +1.0%
INmune Bio shares rose 14.1%, while the S&P 500 rose 1.6%.
+14.1% · S&P 500 +1.6%
EPS of $-0.05 beat the $-0.20 estimate on $0.00 revenue.
+9.2% · S&P 500 +0.6%
INmune Bio closed at its highest level of the year, 65.1% above where the year started.
+2.9% · S&P 500 −0.5%
EPS of $-0.17 beat the $-0.18 estimate on $0.00 revenue.
−3.8% · S&P 500 +0.3%
Where it ended: a close of $1.10 on Nov 10, 2026.
Nothing in the past 12 months.
All INMB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for INMB and SPY from Benzinga historical bars. Not investment advice.
